Abstract
Head and neck cancer includes epithelial malignancies of the upper aerodigestive tract, including the skull base, paranasal sinuses, nasal cavity, oral cavity, naso-, oro- and hypopharynx, larynx and salivary glands, squamous-cell carcinoma being the most prevalent histopathological type. More than 2/3 of patients present at an advanced tumour-stage (III + IV UICC) at time of diagnosis. Although much effort has been done in the research of tumour-specific therapy (e.g. new chemotherapy protocols, induction chemotherapy, targeted therapy, intensity-modulated radiotherapy) the overall survival rates have unfortunately not improved. Learning of their cancer diagnosis and receiving tumour-specific treatment has a great impact on individuals living with the disease and their families. Supportive and palliative care is interdisciplinary care and provides support for the physical, emotional and psychological suffering of patients with any advanced illness, regardless of age, diagnosis or life expectancy. The goal is to prevent and relieve suffering and to improve the quality of life for patients. All patients with a cancer diagnosis need general supportive and palliative care, which represents a wide range of services to help the patients to live as actively as possible until death.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Cognetti DM, Weber RS, Lai SY. Head and neck cancer, an evolving treatment paradigm. Cancer. 2008;113(7 Suppl):1911–32.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467–75.
Fadul N, Elsayem A, Palmer JL, Del Fabbro E, Swint K, Li Z, et al. Supportive versus palliative care: what’s in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer. 2009;119(9):2013–21.
Morstad Boldt A, Yusuf F, Himelstein B. Perceptions of the term palliative care. J Palliat Med. 2006;5:1128–36.
National Consensus Project for Quality Palliative Care. Clinical practice guidelines for quality palliative care. 2004. http://www.nationalconsensusproject.org. Accessed 30 March 2008.
Portenoy RK, Miransky J, Thaler HT, et al. Pain in ambulatory patients with lung or colon cancer: Prevalence, characteristics, and effect. Cancer. 1992;70:1616–24.
Payne R, Gonzales GR. Pathophysiology of pain in cancer and other terminal disease. In: Doyle D, Hanks G, Cherny N, et al., editors. Oxford textbook of palliative medicine. 3rd ed. New York: Oxford University Press; 2005. p. 288–98.
Grossmann SA, Sheidler VR, Swedeen K, et al. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage. 1991;6:53–7.
Agency for Health Care Policy and Research. Cancer Pain Management Panel: Management of Cancer Pain. Washington, DC: U.S. Dept. of Health and Human Services; 1994. Clinical Practice Guidelines Number 9.
Grossman SA, Sheidler VR, McGuire DB, et al. A comparison of the Hopkins pain rating instrument with standard visual analogue and verbal descriptor scales in patients with caner pain. J Pain Symptom Manage. 1992;7(4):196–203.
Schrijvers D. Management of Cancer Pain Professor Session. 2nd European perspectives in head and neck cancer. Prague: Marriott Hotel; 2009.
Cherny NI, Portenoy RK. The management of cancer pain. CA Cancer J Clin. 1994;44:262–303.
Sykes NP. Constipation and diarrhoea. In: Doyle D, Hanks GW, MacDoonald N, editors. Oxford textbook of palliative medicine. New York: Oxford University Press; 1993. p. 299–310.
Campora E, Merlini L, Pace M, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage. 1991;6:428–30.
Greene WR, Davis WH. Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer. South Med J. 1991;84:332–7.
Truog RD, Berde CB, Mitchell C, Greir HE. Barbiturates in the care of the terminally ill. N Engl J Med. 1992;327:1678–82.
Herrstedt J. Prevention and management of mucositis in patients with cancer. Int J Antimicrob Agents. 2000;16:161–3.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Research and Treatment of Cancer(EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
Bourhis J, Etessami A, Lusinchi A. New trend in radiotherapy for head and neck cancer. Ann Oncol. 2005;16 Suppl 2:ii255–7.
Archibald D, Lockhart PB, Sonis ST, et al. Oral complications of multimodality therapy for advanced squamous cell carcinoma of head and neck. Oral Surg Oral Med Oral Pathol. 1986;61:139–41.
Sciubba JJ, Goldenber G. Oral complications of radiotherapy. Lancet Oncol. 2006;7:175–83.
Brizel D, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol. 2003;4:378–81.
Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–8.
Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol. 2006;24(33):5186–93.
Chambers MS. Radiation-induced xerostomia. Head Neck. 2007;29:58–63.
Wescott WB. Alterations in whole saliva flow rate induced by fractionated radiotherapy. AJR Am J Roentgenol. 1978;130(1):145–9.
Keilbasa AM, Hinkelbein W, Hellwig E, Meyer-Lückel H. Radiation-related damage to dentition. Lancet Oncol. 2006;7:326–35.
Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Bil Phys. 2001;50:695–704.
Roesink JM, Konings AW, Terhaard CH, et al. Preservation of the rat parotid gland function after radiation by prophylactic pilocarpine treatment: radiation dose dependency and compensatory mechanisms. Int J Radiat Oncol Biol Phys. 1999;45:483–9.
Vissink A, Johannes’s-Gravenmade E, Panders AK, Vermey A. Treatment of hyposalivation. Ear Nose Throat J. 1988;67:179–85.
Dirix P, Nuyts S, Walter Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer. Cancer. 2006;107:2525–34.
Morrow SG. Mechanism and management of chemotherapy-induced nausea and vomiting. Blood Rev. 1987;1:50–7.
Bakowski MT. Advances in anti-emetic therapy. Cancer Treat Rev. 1984;11:237–56.
Kaye SB. How should nausea be assessed in patients receiving chemotherapy? Cancer Treat Rev. 1991;1:85–93.
Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep. 1982;66:1601–4.
Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm. 1985;10(2):143–66.
Wickham R. Managing chemotherapy-related nausea and vomiting: the state of the art. Oncol Nurs Forum. 1989;16:563–74.
Coons HL, Levanthal H, Nerenz DR, Love RR, Larson S. Anticipatory nausea and emotional distress in patients receiving cisplatin-based chemotherapy. Oncol Nurs Forum. 1987;14(4):31–5.
Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. Cancer J Clin. 1989;39:89–104.
Gralla RJ, Tyson LB, Kris MG, Clark RA. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am. 1987;71(2):289–301.
Andrykowski MA. Definitional issues in the study of anticipatory nausea in cancer chemotherapy. J Behav Med. 1986;9:33–41.
ASCO Patient Guide. 2006 http://www.asco.org/ASCOv2/Press+Center/Latest+News+Releases/ASCO+Releases+Updated+Clinical+Practice+Guideline+on+the+Use+of+Antiemetics+for+Cancer+Patients. Accessed 20 July 2009.
Inui A. Cancer anorexia-cachexia syndrome. CA Cancer J Clin. 2002;52:72–91.
Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol. 2000;1:138–47.
Newman LA, Vierra F, Schwiezer V, et al. Eating and weight changes following chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124:589–92.
Lazarus CL, Logemann JA, Pauloski BR, et al. Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy. Laryngoscope. 1996;106:1157–66.
Chonchinov HM. Depression in cancer patients. Lancet Oncol. 2001;2:499–505.
Nauck F, Al-Epping B. Crises in palliative care – a comprehensive approach. Lancer Oncol. 2008;9:1086–91.
Ciais JF, Pradier C, Ciais C, et al. Impact of a hospice home team on unwanted hospitalisation of terminally-ill patients at home in acute medical emergencies. Presse Méd. 2007;36:404–9.
Klocker JG, Klocker-Kaiser U, Schwaninger M. Truth in the relationship between cancer patient and physician. Ann N Y Acad Sci. 1997;809:56–65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Salzwimmer, M. (2011). Best Supportive Care for Palliative Treatment. In: Bernier, J. (eds) Head and Neck Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9464-6_48
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9464-6_48
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9463-9
Online ISBN: 978-1-4419-9464-6
eBook Packages: MedicineMedicine (R0)